Academic Medical Center, Emma Children's Hospital, Amsterdam, the Netherlands.
Nutricia Research, Utrecht, the Netherlands.
Pediatr Allergy Immunol. 2018 Mar;29(2):151-158. doi: 10.1111/pai.12857. Epub 2018 Feb 7.
Cohort studies have suggested that early-life antibiotic treatment is associated with increased risk of atopy. We determined whether antibiotic treatment already in the first week of life increases the risk of atopic and non-atopic disorders.
The INCA study is a prospective observational birth cohort study of 436 term infants, with follow-up of 1 year; 151 neonates received broad-spectrum antibiotics for suspected neonatal infection (AB+), vs a healthy untreated control group (N = 285; AB-). In the first year, parents recorded daily (non-) allergic symptoms. At 1 year, doctors' diagnoses were registered and a blood sample was taken (n = 205).
Incidence of wheezing in the first year was higher in AB+ than AB- (41.0% vs 30.5%, P = .026; aOR 1.56 [95%CI 0.99-2.46, P = .06]). Infantile colics were more prevalent in AB+ compared to AB- (21.9% and 14.4% P = .048), and antibiotic treatment was an independent risk factor for infantile colics (aOR 1.66 (95%CI 1.00-2.77) P = .05). Allergic sensitization (Phadiatop >0.70kUA/L) showed a trend toward a higher risk in AB+ (aOR 3.26 (95%CI 0.95-11.13) P = .06). Incidence of eczema, infections, and GP visits in the first year were similar in AB+ and AB-.
Antibiotic treatment in the first week of life is associated with an increased risk of wheezing and infantile colics. This study may provide a rationale for early cessation of antibiotics in neonates without proven or probable infection.
队列研究表明,婴儿早期接受抗生素治疗与特应性风险增加有关。我们旨在确定生命早期(1 周内)接受抗生素治疗是否会增加特应性和非特应性疾病的风险。
INCA 研究是一项前瞻性观察性出生队列研究,共纳入 436 例足月婴儿,随访 1 年;151 例新生儿因疑似新生儿感染接受了广谱抗生素治疗(AB+组),而健康未接受治疗的对照组为 285 例(AB-组)。在第 1 年中,父母每天记录(非)过敏症状。在 1 岁时,医生记录了诊断结果并采集了血样(n=205)。
AB+组婴儿在第 1 年中喘息的发生率高于 AB-组(41.0%比 30.5%,P=0.026;优势比 1.56[95%可信区间 0.99-2.46],P=0.06)。AB+组婴儿绞痛的发生率高于 AB-组(21.9%比 14.4%,P=0.048),抗生素治疗是绞痛的独立危险因素(优势比 1.66[95%可信区间 1.00-2.77],P=0.05)。过敏致敏(Phadiatop>0.70kUA/L)在 AB+组中呈更高风险趋势(优势比 3.26[95%可信区间 0.95-11.13],P=0.06)。AB+组和 AB-组在第 1 年中特应性皮炎、感染和 GP 就诊的发生率相似。
生命早期(1 周内)接受抗生素治疗与喘息和婴儿绞痛风险增加相关。本研究可能为没有明确或可能感染的新生儿尽早停止抗生素治疗提供了依据。